YESTAR HEALTH (02393) issues profit warning, expecting a significant decrease in mid-term comprehensive net profit to not less than RMB 10 million.

YESTAR HEALTH (02393) announced that compared to the unaudited comprehensive net profit of approximately RMB 1.093 billion for the six months ended June 30, 2024, the group expects the unaudited comprehensive net profit for the six months ended June 30, 2025 to decrease significantly to not less than RMB 10 million. The expected significant decrease in the group's net profit during the mid-year of 2025 is mainly due to (i) the lack of surplus profit of approximately RMB 1.083 billion recognized in the mid-year of 2024 from the redemption of the company's preferred notes due in 2026 at a discounted price; and (ii) a decrease in revenue from the medical products division.